GLP1
GLP1
+1
Oct 6, 2026
•
10 min read
23.3% Weight Loss in Type 2 Diabetes. Can Patients Stay on Treatment?
In a randomized Phase 2b trial, Lilly’s amylin-plus-tirzepatide combination showed 8.5 percentage points greater estimated weight loss than tirzepatide 15 mg. The open question is how many people can stay on it.
GLP1
+1
Oct 3, 2026
•
18 min read
Glucagon Was the Villain. Amylin Was a Footnote.
A mechanism-first deep dive into the two hormones behind the next obesity drugs: what they do in the liver and the brainstem, and what the trials can and can't confirm.
GLP1
+1
Sep 30, 2026
•
17 min read
Everyone Will Quote 28%. Read Page Four.
TRIUMPH-1 is in NEJM. The obvious findings first, then what's hiding underneath.
GLP1
+3
Sep 23, 2026
•
11 min read
Twenty-Five Trials on Binge Eating. Three Studied It.
A new meta-analysis says GLP-1s reduce binge eating. It's the most rigorous synthesis we have, and the part that answers the question rests on about 130 patients.
GLP1
+1
Sep 8, 2026
•
4 min read
Two Free Tools to Make Sense of Obesity Medications
A trial tracker and a medication comparison, free for clinicians and curious patients, plus one methods detail that changes how you read weight loss trials.
GLP1
+4
Aug 25, 2026
•
13 min read
Half the Pancreas Is Already Gone. Then We Start Slow.
Type 2 diabetes is endocrine pancreatic failure — and we diagnose it by its last symptom, then treat it with our weakest tools during the only window that reliably reverses it.
Coverage
+4
Aug 8, 2026
•
13 min read
Every First Claim Is Denied. That's the Design.
One month into the Medicare GLP-1 Bridge, the denial at the counter isn't a coverage decision — and CMS built no appeals process for the ones that are.
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
GLP1
+3
Jul 28, 2026
•
4 min read
The Triple Agonist, in Plain Numbers
Retatrutide is posting some of the largest weight-loss numbers the incretin class has seen. Here's what the data actually says — and the two things to watch before the headline. Free cheat sheet inside.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
GLP1
+2
Jul 11, 2026
•
6 min read
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
GLP1
+1
Jul 7, 2026
•
3 min read
I Built a Live Index of Every Obesity Drug Trial
The pipeline moves faster than any newsletter can. So I stopped trying to summarize it and built something that updates itself.
GLP1
+2
Jul 4, 2026
•
11 min read
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
GLP1
+1
Jun 27, 2026
•
10 min read
The patient barely lost weight. He got better anyway.
What the newest trial data reveal about GLP-1 medicines, and why "weight loss drug" may be the least interesting thing about them.
GLP1
+2
Jun 23, 2026
•
8 min read
Medicare Will Pay for Wegovy Now. Here's the Catch.
Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
GLP1
+1
Jun 6, 2026
•
7 min read
GLP-1 Resistance Is Real. You Probably Don’t Have It.
A genetic study just caught true GLP-1 resistance in the act. Almost no one being called a “non-responder” fits the description.
GLP1
+1
May 23, 2026
•
9 min read
The Accidental Hormone.
A century-long hunt for a phantom gut hormone, a peptide chemist written out of the story, and a venomous desert lizard. Here is where Ozempic actually comes from — and who actually found it.
GLP1
+2
May 19, 2026
•
13 min read
ECO 2026: The Maintenance Era Begins.
Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.
GLP1
+2
Apr 22, 2026
•
17 min read
Before or After? The GLP-1 and Surgery Sequencing Question
The science of sequencing GLP-1 therapy and bariatric surgery — and why the answer is more complicated than anyone wants to admit.
GLP1
+2
Apr 8, 2026
•
14 min read
The Longevity Stack
Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.
GLP1
+3
Mar 27, 2026
•
15 min read
What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.